Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SYMTUZA safely and effectively. See full prescribing information for SYMTUZA. SYMTUZA® (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-prescription
SYMTUZA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg: who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.
- generic_name
- darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
- product_names
- Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide
- ndc
- 59676-800, 59676-800-30, 59676-800-99
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en